deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 2-arm NCT03671811

Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy

Open-Label Randomized Phase II Trial of Megestrol Acetate With or Without Pterostilbene in Patients With Endometrial Cancer Scheduled for Hysterectomy

Sponsor: City of Hope Medical Center

Conditions Atypical Endometrial Hyperplasia Endometrial Carcinoma
Interventions Megestrol Acetate Pterostilbene
Updated 17 times since 2018 Last updated: Dec 31, 2025 Started: Jan 21, 2019 Primary completion: Dec 12, 2022 Completion: Mar 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Atypical Endometrial Hyperplasia and Endometrial Carcinoma and is currently ongoing. City of Hope Medical Center leads this study, which shows 17 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Oct 2018 – ~Jan 2019 · 3 months · monthly snapshot~Jan 2019 – ~Apr 2019 · 3 months · monthly snapshot~Apr 2019 – ~Sep 2019 · 5 months · monthly snapshot~Sep 2019 – ~Jan 2021 · 16 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Jul 2022 · 10 months · monthly snapshot~Jul 2022 – ~Nov 2022 · 4 months · monthly snapshot~Nov 2022 – ~Apr 2023 · 5 months · monthly snapshot~Apr 2023 – ~Feb 2024 · 10 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~Apr 2025 · 3 months · monthly snapshot~Apr 2025 – ~Jun 2025 · 2 months · monthly snapshot~Jun 2025 – ~Feb 2026 · 8 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

17 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Jun 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE2

  3. Apr 2025 — Jun 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jan 2025 — Apr 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE2

▶ Show 12 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Feb 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Apr 2023 — Feb 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Nov 2022 — Apr 2023 [monthly]

    Recruiting PHASE2

  5. Jul 2022 — Nov 2022 [monthly]

    Recruiting PHASE2

  6. Sep 2021 — Jul 2022 [monthly]

    Recruiting PHASE2

  7. Apr 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  8. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  9. Sep 2019 — Jan 2021 [monthly]

    Recruiting PHASE2

  10. Apr 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

  11. Jan 2019 — Apr 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  12. Oct 2018 — Jan 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • City of Hope Medical Center
  • National Cancer Institute (NCI)
Data source: City of Hope Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations